Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...
Forbes

What's Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Business Wire

Dr. Imran S. Haque, Biology Machine Learning Expert, Joins Recursion as VP of Data Science

SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...
Business Wire

Splunk Machine Learning Helps Recursion Pharmaceuticals Treat Genetic Diseases

SAN FRANCISCO--(BUSINESS WIRE)--Splunk Inc. (NASDAQ: SPLK), first in delivering “aha” moments from machine data, today announced biotechnology company Recursion Pharmaceuticals is using Splunk® ...
Forbes

Recursion Announces New Generative AI Platform To Speed Up Drug Discovery

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
ZDNet

The subtle art of really big data: Recursion Pharma maps the body

Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...